keyword
MENU ▼
Read by QxMD icon Read
search

Revlimid

keyword
https://www.readbyqxmd.com/read/27668061/revlimid-lenalidomide-now-fda-approved-as-first-line-therapy-for-patients-with-multiple-myeloma
#1
Lisa A Raedler
No abstract text is available yet for this article.
March 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27544800/double-hit-follicular-lymphoma-with-myc-and-bcl2-translocations-a-study-of-7-cases-with-a-review-of-literature
#2
Yuan Miao, Shimin Hu, Xinyan Lu, Shaoying Li M D, Wei Wang, L Jeffrey Medeiros, Pei Lin
Follicular lymphoma (FL) with MYC and BCL2 translocations, so-called double-hit follicular lymphoma (DH-FL), is rare. Here we report the clinicopathologic features of 7 cases of DH-FL. All neoplasms had a follicular pattern (1 partially diffuse). Five cases were of predominantly low grade, 4 of which had focal (≤ 20%) grade 3 A areas, and 2 cases were of grade 3. All cases were positive for pan B-cell antigens, CD10 and BCL6; 6 cases were positive for BCL2. Ki67 was ≤50% in 6 cases and 90% in one grade 3 case...
August 17, 2016: Human Pathology
https://www.readbyqxmd.com/read/27441522/diarrhea-in-multiple-myeloma-a-review-of-the-literature
#3
Beth Faiman
BACKGROUND: One of the most common and inadequately managed symptoms that patients with multiple myeloma (MM) experience as a result of cancer treatment is diarrhea. Diarrhea in patients with MM often is severe enough to warrant dose reduction, delays, or discontinuation of chemotherapy. Short-term diarrhea can occur as a side effect of drugs, such as bortezomib (Velcade®) or panobinostat (Farydak®). Late-onset diarrhea from lenalidomide (Revlimid®) can occur 17-24 months after the start of therapy...
August 1, 2016: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/27162471/lenalidomide-revlimid-a-thalidomide-analogue-in-combination-with-dexamethasone-for-the-treatment-of-all-patients-with-multiple-myeloma
#4
Martin Paspe Cruz
No abstract text is available yet for this article.
May 2016: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/26321720/-a-newly-diagnosed-case-of-multiple-myeloma-in-which-lenalidomide-was-continued-after-surgery-for-a-pancreatic-neuroendocrine-tumor-that-developed-during-lenalidomide-maintenance-therapy
#5
Hiroyuki Kuroda, Masahiro Yoshida, Makoto Usami, Saori Shimoyama, Hiroki Sakamoto, Michiko Yamada, Shigeyuki Fujii, Masahiro Maeda, Miri Fujita, Yusuke Kanari, Tsutomu Sato, Junji Kato
A 75-year-old woman was diagnosed with symptomatic IgG-l multiple myeloma (good-prognosis group) in December 2010. A stringent complete response (sCR) was achieved by using induction therapy with bortezomib (BOR, Velcade®)+ dexamethasone (DEX)(VD) and consolidation therapy with BOR+lenalidomide (LEN, Revlimid®)+DEX(VRD). Although maintenance therapy with Revlimid®+DEX(Rd) was initiated, a pancreatic neuroendocrine tumor was detected in April 2013. Therefore, LEN was discontinued and distal pancreatectomy was performed in September 2013...
August 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/25925941/lenalidomide-a-review-of-its-continuous-use-in-patients-with-newly-diagnosed-multiple-myeloma-not-eligible-for-stem-cell-transplantation
#6
REVIEW
Paul L McCormack
Lenalidomide (Revlimid(®)) is a second-generation immunomodulatory drug structurally related to thalidomide, with improved efficacy and tolerability, for which the label in the EU was recently expanded to include continuous therapy in patients with previously untreated multiple myeloma not eligible for stem-cell transplantation. In randomized, controlled clinical trials, continuous lenalidomide therapy, either in combination with dexamethasone (FIRST trial) or as maintenance monotherapy following induction with melphalan/prednisone/lenalidomide (MM-015 trial), significantly improved progression-free survival (PFS) compared with induction therapy alone (with non-lenalidomide- or lenalidomide-containing regimens) in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation...
May 2015: Drugs & Aging
https://www.readbyqxmd.com/read/25342294/severe-resistant-hypocalcemia-in-multiple-myeloma-after-zoledronic-acid-administration-a-case-report
#7
Adrian P Noriega Aldave, Shikha Jaiswal
INTRODUCTION: Hypercalcemia is one of the most common metabolic abnormalities encountered in any form of malignancy. Hypocalcemia, however, is a rare manifestation, especially in cancers with bone involvement. Here we present a case of hypocalcemia in a patient with multiple myeloma that was refractory to treatment. CASE PRESENTATION: A 73-year-old African American woman recently diagnosed with multiple myeloma, presented with a 2-day history of fever, vomiting and hypocalcemia...
October 23, 2014: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/25248908/-three-cases-of-lenalidomide-resistant-iga-myeloma-for-which-a-response-was-regained-after-the-addition-of-clarithromycin
#8
Hiroyuki Kuroda, Wataru Jomen, Masahiro Yoshida, Makoto Usami, Michiko Yamada, Tomoyuki Abe, Tamaki Sakurai, Shigeyuki Fujii, Masahiro Maeda, Teppei Matsuno, Masanori Sato, Yusuke Kanari, Junji Kato
BiRd combination therapy, which comprises clarithromycin (CAM: Biaxin®), lenalidomide (LEN: Revlimid®), and dexamethasone ( DEX), is a highly effective treatment for newly diagnosed symptomatic myeloma. However, its efficacy against recurrent myeloma refractory to combination therapy with LEN and DEX(Rd therapy) remains unclear. Here, we report on BiRd therapy administered to three patients with IgA myeloma exacerbated during Rd therapy and for whom transplantation was not indicated, by adding CAM to the Rd regimen...
September 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/25188483/current-advances-in-non-proteasome-inhibitor-based-approaches-to-the-treatment-of-relapsed-refractory-multiple-myeloma
#9
REVIEW
Abhishek Singla, Shaji Kumar
In the past decade, immunomodulatory drugs have been approved by the US Food and Drug Administration for the treatment of multiple myeloma (MM)-and a number of emerging agents that target the cellular pathways or proteins involved in the pathophysiology of MM are currently in development. Lenalidomide (Revlimid) and pomalidomide induce apoptosis and sensitize MM cells while demonstrating superior efficacy and better tolerability than thalidomide (Thalomid). Several novel classes of drugs, including the histone deacetylase (HDAC) inhibitors, heat shock protein (HSP) inhibitors, and monoclonal antibodies have been shown to have activity in myeloma in early-stage clinical trials...
November 15, 2011: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/25188481/treatment-related-adverse-events-in-patients-with-relapsed-refractory-multiple-myeloma
#10
REVIEW
Ravi Vij
In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin. These are commonly used in the treatment of relapsed/refractory (R/R) multiple myeloma (MM), but there is no universally accepted standard treatment. Salvage therapy must be tailored according to an individual patient's clinical profile, with the risks and potential effects of treatment-related adverse events being major determinants of the choice of therapy...
November 15, 2011: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/25146584/phase-i-ii-trial-of-oral-cyclophosphamide-prednisone-and-lenalidomide-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma
#11
Donna E Reece, Esther Masih-Khan, Eshetu G Atenafu, Victor H Jimenez-Zepeda, Peter Anglin, Christine Chen, Vishal Kukreti, Joseph R Mikhael, Suzanne Trudel
This single institution, open label Phase I-II dose escalation trial evaluated the safety and efficacy of the combination of lenalidomide (Revlimid®), cyclophosphamide and prednisone (CPR) in patients with relapsed/refractory multiple myeloma. The maximal administered dose of CPR consisted of cyclophosphamide 300 mg/m(2) on day 1, 8, and 15, lenalidomide 25 mg on d 1-21 and prednisone 100 mg every other day in a 28-d cycle. Between November 2007 and June 2009, 32 patients were entered in cohorts of three at three dose levels...
January 2015: British Journal of Haematology
https://www.readbyqxmd.com/read/24739012/tumour-necrosis-factor-%C3%AE-inhibition-with-lenalidomide-alleviates-tissue-oxidative-injury-and-apoptosis-in-ob-ob-obese-mice
#12
Xiaoling Zhu, Shasha Jiang, Nan Hu, Fuling Luo, Hailong Dong, Yu-Ming Kang, Kyla R Jones, Yunzeng Zou, Lize Xiong, Jun Ren
Lenalidomide (Revlimid; Selleck Chemicals, Houston, TX, USA), an analogue of thalidomide, possesses potent cytokine modulatory capacity through inhibition of cytokines such as tumour necrosis factor (TNF)-α, a cytokine pivotal for the onset and development of complications in obesity and diabetes mellitus. The present study was designed to evaluate the effect of lenalidomide on oxidative stress, protein and DNA damage in multiple organs in an ob/ob murine model of obesity. To this end, C57BL/6 lean and ob/ob obese mice were administered lenalidomide (50 mg/kg per day, p...
July 2014: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/24724748/treatment-with-lenalidomide-revlimid%C3%A2-cyclophosphamide-endoxan%C3%A2-and-prednisone-rep-in-relapsed-refractory-multiple-myeloma-patients-results-of-a-single-centre-retrospective-study
#13
N Zelis, T Devos, D Dierickx, A Janssens, J Raddoux, G Verhoef, M Delforge
Lenalidomide (Revlimid®) combined with intermittent dexamethasone (the RD regimen) is one of the current standards for treatment of patients with relapsed/refractory multiple myeloma (MM). However, since the disease in the majority of patients will become resistant to RD, or treatment with RD needs to be discontinued due to side effects, we evaluated the combination lenalidomide, low-dose oral cyclophosphamide, with prednisone (REP) in patients with relapsed/refractory MM previously exposed to RD. For this purpose, we performed a single centre retrospective study of the efficacy of REP in 19 patients with relapsed/refractory MM...
April 2014: Acta Clinica Belgica
https://www.readbyqxmd.com/read/24576165/thalidomide-clarithromycin-lenalidomide-and-dexamethasone-therapy-in-newly-diagnosed-symptomatic-multiple-myeloma
#14
Tomer M Mark, Isaac A Bowman, Adriana C Rossi, Manan Shah, Melissa Rodriguez, Ryann Quinn, Roger N Pearse, Faiza Zafar, Karen Pekle, David Jayabalan, Scott Ely, Morton Coleman, Selina Chen-Kiang, Ruben Niesvizky
We studied T-BiRD (thalidomide [Thalomid(®)], clarithromycin [Biaxin(®)], lenalidomide [Revlimid(®)] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma. In 28-day cycles, patients received dexamethasone 40 mg/day on days 1, 8, 15, 22, clarithromycin 500 mg twice daily on days 1-28; lenalidomide 25 mg/day on days 1-21; and thalidomide 100 mg/day (50 mg/day on days 1-7 of cycle 1 only) on days 1-28. Twenty-six patients received a median of 6 cycles (range 0-41). Overall response rate (ORR) was 80% for the group and 100% in 11 patients who underwent autologous stem cell transplantation as part of first-line therapy...
December 2014: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/24137269/analysis-of-the-efficacy-of-lenalidomide-in-patients-with-intermediate-1-risk-myelodysplastic-syndrome-without-5q-deletion
#15
Yan Yang, Sujun Gao, Hongqiong Fan, Hai Lin, Wei Li, Juan Wang
The aim of this study was to evaluate the efficacy and adverse effects of lenalidomide in the treatment of intermediate-1 risk non-5q deletion [non-del (5q)] myelodysplastic syndrome (MDS). A total of 30 patients with MDS were classified through G-banding chromosome karyotype analysis and fluorescence in situ hybridization (FISH). According to the International Prognostic Scoring System scores, among the 30 patients, 23 and seven cases had scores of 0.5 and 1.0, respectively. Lenalidomide (Revlimid(®)), 10 mg/day) was administered for 21 days every 28 days...
September 2013: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/23824699/lenalidomide-a-review-of-its-use-in-patients-with-transfusion-dependent-anaemia-due-to-low-or-intermediate-1-risk-myelodysplastic-syndrome-associated-with-5q-chromosome-deletion
#16
REVIEW
Yahiya Y Syed, Lesley J Scott
Lenalidomide (Revlimid(®)), a thalidomide analogue, is an orally administered second generation immunomodulator with anti-angiogenic, antineoplastic, anti-inflammatory and pro-erythropoietic properties. It is approved for the treatment of patients with transfusion-dependent anaemia due to International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome (MDS) associated with either chromosome 5q deletion [del(5q)] with or without additional cytogenetic abnormalities (US, Japan and Switzerland etc...
July 2013: Drugs
https://www.readbyqxmd.com/read/23731832/a-phase-2-multicentre-single-arm-open-label-study-to-evaluate-the-safety-and-efficacy-of-single-agent-lenalidomide-revlimid-in-subjects-with-relapsed-or-refractory-peripheral-t-cell-non-hodgkin-lymphoma-the-expect-trial
#17
MULTICENTER STUDY
Franck Morschhauser, Olivier Fitoussi, Corinne Haioun, Catherine Thieblemont, Hang Quach, Richard Delarue, Sylvie Glaisner, Jean Gabarre, André Bosly, John Lister, Ju Li, Bertrand Coiffier
BACKGROUND: This multicentre, single-arm, open-label phase 2 trial investigated the efficacy and safety of lenalidomide monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). METHODS: Patients received oral lenalidomide 25mg once daily on days 1-21 of each 28-day cycle for a maximum of 24 months, until disease progression or development of unacceptable adverse events (AEs). The primary end-point was efficacy; safety was evaluated as a secondary end-point...
September 2013: European Journal of Cancer
https://www.readbyqxmd.com/read/23691202/lenalidomide-treatment-for-multiple-myeloma-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#18
REVIEW
Bo Yang, Rui-li Yu, Xiao-hua Chi, Xue-chun Lu
BACKGROUND: In recent years, a number of randomized controlled trials (RCTs) have reported on lenalidomide as a treatment for multiple myeloma (MM). Herein, we report results of a meta-analysis of RCTs examining the efficacy and safety of lenalidomide for MM. PATIENTS AND METHODS: Databases were searched using the terms "lenalidomide or revlimid AND multiple myeloma."RCTs evaluating initial or maintenance therapeutic outcomes were included. Main outcome measures were response rates, progression-free survival (PFS), overall survival, and adverse events...
2013: PloS One
https://www.readbyqxmd.com/read/23545923/use-of-lenalidomide-in-treating-refractory-prurigo-nodularis
#19
Hannah Liu, Anthony A Gaspari, Rachel Schleichert
Prurigo nodularis is a chronic, relapsing neurodermatitis that is often resistant to standard therapies with topical corticosteroids and oral antihistamines. Thalidomide, while efficacious in treating recalcitrant cases of prurigo nodularis, causes significant toxicity. Thalidomide-induced peripheral neuropathy frequently results in drug discontinuation. Lenalidomide (Revlimid; Celgene Corporation, Summit, NJ) is a derivative of thalidomide with less neurotoxicity approved for the treatment of multiple myeloma and myelodysplastic syndromes that has not been widely studied in dermatologic disorders...
March 2013: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/23510862/sargramostim-gm-csf-and-lenalidomide-in-castration-resistant-prostate-cancer-crpc-results-from-a-phase-i-ii-clinical-trial
#20
Jorge A Garcia, Paul Elson, Allison Tyler, Pierre Triozzi, Robert Dreicer
BACKGROUND: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic cytokine that stimulates dendritic cells (DCs) and promotes uptake of tumor antigens by DCs leading to T-cell cross-priming. Lenalidomide (Revlimid) is an immunomodulatory analog of thalidomide with significant T-cell stimulatory and antiangiogenic properties. GM-CSF in combination with thalidomide induces prostate-specific antigen (PSA) responses in 20% to 25% of patients with castration-resistant prostate cancer (CRPC)...
January 2014: Urologic Oncology
keyword
keyword
12312
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"